Related references
Note: Only part of the references are listed.Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition
Jonas Kunst et al.
BRAIN TOPOGRAPHY (2019)
Post hoc analysis of the Exenatide-PD trial-Factors that predict response
Dilan Athauda et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2019)
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies
Kurt A. Jellinger
JOURNAL OF NEURAL TRANSMISSION (2018)
Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study
David S. Knopman et al.
ALZHEIMERS & DEMENTIA (2018)
Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
Kurt A. Jellinger et al.
BMC MEDICINE (2018)
C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease
Abdelrahman Ibrahim Abushouk et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2018)
The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update
Rita Khoury et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Subjective Cognitive Complaints and Objective Cognitive Impairment in Parkinson's Disease
Jin Yong Hong et al.
JOURNAL OF CLINICAL NEUROLOGY (2018)
Network imaging biomarkers: insights and clinical applications in Parkinson's disease
Katharina A. Schindlbeck et al.
LANCET NEUROLOGY (2018)
Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment
Irene Litvan et al.
MOVEMENT DISORDERS (2018)
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Steven E. Arnold et al.
NATURE REVIEWS NEUROLOGY (2018)
Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
Liping Zhang et al.
NEUROPEPTIDES (2018)
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
Dilan Athauda et al.
NEUROPHARMACOLOGY (2018)
Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models
Christian Holscher
NEUROPHARMACOLOGY (2018)
A review of brain insulin signaling in mood disorders: From biomarker to clinical target
Thanh Thanh L. Nguyen et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2018)
Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications
Roberta Balestrino et al.
NEUROSCIENTIST (2018)
Progression of Cognitive Decline in Parkinson's Disease
Mandy Roheger et al.
JOURNAL OF PARKINSONS DISEASE (2018)
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study
Chieh-Hsiang Lu et al.
DIABETOLOGIA (2018)
Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease
Amanda Calhoun et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
The diabetic brain and cognition
Peter Riederer et al.
JOURNAL OF NEURAL TRANSMISSION (2017)
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
John T. O'Brien et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Dementia in Parkinson's disease
Hasmet A. Hanagasi et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Yan Zhang et al.
NATURE (2017)
Cognitive decline in Parkinson disease
Dag Aarsland et al.
NATURE REVIEWS NEUROLOGY (2017)
Serum IGF-1 is associated with cognitive functions in early, drug-naive Parkinson's disease
Marina Picillo et al.
PLOS ONE (2017)
Efficacy, Safety, and Tolerability of Armodafinil Therapy for Hypersomnia Associated with Dementia with Lewy Bodies: A Pilot Study
Maria I. Lapid et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2017)
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample
Prashanthi Vemuri et al.
ANNALS OF NEUROLOGY (2017)
Synaptic proteins in CSF relate to Parkinson's disease stage markers
Erika Bereczki et al.
NPJ PARKINSONS DISEASE (2017)
A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway
Dong Seok Kim et al.
CELL TRANSPLANTATION (2017)
Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
Shinji Matsunaga et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease
Mark Terrelonge et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2016)
Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology
Erin L. Abner et al.
ALZHEIMERS & DEMENTIA (2016)
Ceftriaxone prevents the neurodegeneration and decreased neurogenesis seen in a Parkinson's disease rat model: An immunohistochemical and MRI study
Jun-Cheng Weng et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments
Tangui Maurice
BEHAVIOURAL BRAIN RESEARCH (2016)
Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors
Stephen M. Stahl
CNS SPECTRUMS (2016)
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Dilan Athauda et al.
DRUG DISCOVERY TODAY (2016)
Distribution and Load of Amyloid-β Pathology in Parkinson Disease and Dementia with Lewy Bodies
Dagmar H. Hepp et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2016)
Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies
Xuejing Yue et al.
MEDICINE (2016)
Imaging Synucleinopathies
David J. Brooks et al.
MOVEMENT DISORDERS (2016)
Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitorsA nationwide case-control study
Per Svenningsson et al.
MOVEMENT DISORDERS (2016)
Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease
Naveed Malek et al.
MOVEMENT DISORDERS (2016)
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
Sara Hall et al.
MOVEMENT DISORDERS (2016)
INTRANASAL INSULIN PROTECTS AGAINST SUBSTANTIA NIGRA DOPAMINERGIC NEURONAL LOSS AND ALLEVIATES MOTOR DEFICITS INDUCED BY 6-OHDA IN RATS
Y. Pang et al.
NEUROSCIENCE (2016)
Insulin resistance and Parkinson's disease: A new target for disease modification?
D. Athauda et al.
PROGRESS IN NEUROBIOLOGY (2016)
Recent global trends in the prevalence and incidence of dementia, and survival with dementia
Martin Prince et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
The Differentiation of Amnestic Type MCI from the Non-Amnestic Types by Structural MRI
Gabor Csukly et al.
FRONTIERS IN AGING NEUROSCIENCE (2016)
Nilotinib - Differentiating the Hope from the Hype
Richard K. Wyse et al.
JOURNAL OF PARKINSONS DISEASE (2016)
Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies
Fernando Pagan et al.
JOURNAL OF PARKINSONS DISEASE (2016)
IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases
Amina El Ayadi et al.
EXPERIMENTAL BRAIN RESEARCH (2016)
The Genetic Basis of Cognitive impairment and Dementia in Parkinson's Disease
Lucy M. Collins et al.
FRONTIERS IN PSYCHIATRY (2016)
Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors
Felix P. Bernhard et al.
PLOS ONE (2016)
Localization of PPAR isotypes in the adult mouse and human brain
Anna Warden et al.
SCIENTIFIC REPORTS (2016)
Insulin resistance predicts brain amyloid deposition in late middle-aged adults
Auriel A. Willette et al.
ALZHEIMERS & DEMENTIA (2015)
PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation
Stefan Trapp et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2015)
Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity
Claudia A. Grillo et al.
DIABETES (2015)
Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling
Shanshan Gao et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2015)
Cognitive function in patients with diabetes mellitus: guidance for daily care
Paula S. Koekkoek et al.
LANCET NEUROLOGY (2015)
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)
Chadwick W. Christine
LANCET NEUROLOGY (2015)
Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study
Eugenia Mamikonyan et al.
MOVEMENT DISORDERS (2015)
MDS clinical diagnostic criteria for Parkinson's disease
Ronald B. Postuma et al.
MOVEMENT DISORDERS (2015)
MDS research criteria for prodromal Parkinson's disease
Daniela Berg et al.
MOVEMENT DISORDERS (2015)
Type 2 diabetes mellitus and biomarkers of neurodegeneration
Chris Moran et al.
NEUROLOGY (2015)
Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia
Chao-Yu Hsu et al.
NEUROPHARMACOLOGY (2015)
NEUROPROTECTIVE EFFECTS OF LIXISENATIDE AND LIRAGLUTIDE IN THE 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MOUSE MODEL OF PARKINSON'S DISEASE
W. Liu et al.
NEUROSCIENCE (2015)
Biomarkers of cognitive decline in Parkinson's disease
Chin-Hsien Lin et al.
PARKINSONISM & RELATED DISORDERS (2015)
Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner
Sandeep K. Sharma et al.
SCIENTIFIC REPORTS (2015)
Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study
Ruth Brauer et al.
PLOS MEDICINE (2015)
Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease
David C. Backstrom et al.
JAMA NEUROLOGY (2015)
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis
Hui-Fu Wang et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Alberto Lleo et al.
NATURE REVIEWS NEUROLOGY (2015)
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni et al.
LANCET NEUROLOGY (2015)
Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
Mi Yeon Kang et al.
ENDOCRINOLOGY AND METABOLISM (2015)
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease
Iciar Aviles-Olmos et al.
JOURNAL OF PARKINSONS DISEASE (2014)
Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases
Christian Hoelscher
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Brain Changes Underlying Cognitive Dysfunction in Diabetes: What Can We Learn From MRI?
Geert Jan Biessels et al.
DIABETES (2014)
Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug- na_iveParkinson's disease
M. T. Pellecchia et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Insulin and insulin-like growth factor receptors in the brain: Physiological and pathological aspects
Haim Werner et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors
Toshirou Nishida et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease?
Roberto Erro et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2014)
Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration
Lindsay J. Spielman et al.
JOURNAL OF NEUROIMMUNOLOGY (2014)
Magnitude of Cognitive Dysfunction in Adults with Type 2 Diabetes: A Meta-analysis of Six Cognitive Domains and the Most Frequently Reported Neuropsychological Tests Within Domains
Priya Palta et al.
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY (2014)
The neurobiological basis of cognitive impairment in Parkinson's disease
Glenda M. Halliday et al.
MOVEMENT DISORDERS (2014)
System-based approaches to decode the molecular links in Parkinson's disease and diabetes
Jose A. Santiago et al.
NEUROBIOLOGY OF DISEASE (2014)
Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates
Christine Swanson et al.
NEUROLOGICAL RESEARCH (2014)
Initial cognitive decline is associated with cortical thinning in early Parkinson disease
Joana B. Pereira et al.
NEUROLOGY (2014)
Diabetes and Risk of Parkinson's Disease: An Updated Meta-Analysis of Case-Control Studies
Lin Lu et al.
PLOS ONE (2014)
Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia
Chon-Haw Tsai et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2014)
Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions
Geert Jan Biessels et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort
Sophie E. Winder-Rhodes et al.
BRAIN (2013)
Cerebrospinal fluid inflammatory markers in Parkinson's disease - Associations with depression, fatigue, and cognitive impairment
Daniel Lindqvist et al.
BRAIN BEHAVIOR AND IMMUNITY (2013)
Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence
Sara Varanese et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2013)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Rivastigmine Is Associated With Restoration of Left Frontal Brain Activity in Parkinson's Disease
Katherine L. Possin et al.
MOVEMENT DISORDERS (2013)
Measuring mild cognitive impairment in patients with Parkinson's disease
Connie Marras et al.
MOVEMENT DISORDERS (2013)
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
David J. Irwin et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study
Kim T. E. Olde Dubbelink et al.
NEUROBIOLOGY OF AGING (2013)
Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis
Angie A. Kehagia et al.
NEURODEGENERATIVE DISEASES (2013)
Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease
Valentine Lahmy et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes
Jose A. Santiago et al.
PLOS ONE (2013)
Shared dysregulated pathways lead to Parkinson's disease and diabetes
Jose A. Santiago et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease
Giuseppa Mudo et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Clinical Validity of the Mattis Dementia Rating Scale-2 in Parkinson Disease With MCI and Dementia
Evelyne Matteau et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2012)
GLP-1 secretion by microglial cells and decreased CNS expression in obesity
Camilla Kappe et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Dementia is associated with Insulin Resistance in patients with Parkinson's Disease
Domenico Bosco et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2012)
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Per Svenningsson et al.
LANCET NEUROLOGY (2012)
Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study
Bruno Dubois et al.
MOVEMENT DISORDERS (2012)
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
Irene Litvan et al.
MOVEMENT DISORDERS (2012)
PI3K signalling: the path to discovery and understanding
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Clinical features of Parkinson disease when onset of diabetes came first A case-control study
E. Cereda et al.
NEUROLOGY (2012)
Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis
Yazhou Li et al.
PLOS ONE (2012)
Serum Insulinlike Growth Factor 1 as Possible Marker for Risk and Early Diagnosis of Parkinson Disease
Jana Godau et al.
ARCHIVES OF NEUROLOGY (2011)
The cholinergic system and Parkinson disease
Nicolaas I. Bohnen et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease
Joanne Clark et al.
BMC MEDICAL GENETICS (2011)
Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data
Teus van Laar et al.
CNS NEUROSCIENCE & THERAPEUTICS (2011)
Diabetes and the Risk of Developing Parkinson's Disease in Denmark
Eva Schernhammer et al.
DIABETES CARE (2011)
Diabetes and Risk of Parkinson's Disease
Qun Xu et al.
DIABETES CARE (2011)
Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb
Tomoko Kuwabara et al.
EMBO MOLECULAR MEDICINE (2011)
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
Christine R. Swanson et al.
JOURNAL OF NEUROINFLAMMATION (2011)
Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative
Vanessa Villard et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
The interplay of cholinergic function, attention, and falls in Parkinson's disease
Alison Yarnall et al.
MOVEMENT DISORDERS (2011)
Prediction of Dementia by Subjective Memory Impairment Effects of Severity and Temporal Association With Cognitive Impairment
Frank Jessen et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease
Farhad Mashayekhi et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study
Guido Alves et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine(2A) Inverse Agonist for the Treatment of Insomnia
Hussien A. Al-Shamma et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Murat Emre et al.
LANCET NEUROLOGY (2010)
Mild cognitive impairment in Parkinson disease A multicenter pooled analysis
D. Aarsland et al.
NEUROLOGY (2010)
PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
Bin Zheng et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Rescue of α-synuclein cytotoxicity by insulin-like growth factors
Shyan-Yuan Kao
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Caroline H. Williams-Gray et al.
BRAIN (2009)
α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson's disease models
Tetyana Duka et al.
FASEB JOURNAL (2009)
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Dag Aarsland et al.
LANCET NEUROLOGY (2009)
Atomoxetine for the Treatment of Executive Dysfunction in Parkinson's Disease: A Pilot Open-Label Study
Laura Marsh et al.
MOVEMENT DISORDERS (2009)
Randomized Controlled Trial of Memantine in Dementia Associated with Parkinson's Disease
Iracema Leroi et al.
MOVEMENT DISORDERS (2009)
Distinct Patterns of Regional Cerebral Glucose Metabolism in Parkinson's Disease with and without Mild Cognitive Impairment
Yoshiyuki Hosokai et al.
MOVEMENT DISORDERS (2009)
Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease
Jane A. Driver et al.
DIABETES CARE (2008)
Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease
Goran Bertilsson et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2008)
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Mariese A. Hely et al.
MOVEMENT DISORDERS (2008)
Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation
Linda B. Moran et al.
NEUROGENETICS (2008)
Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats
Randy L. Hunter et al.
NEUROSCIENCE LETTERS (2008)
Clinical diagnostic criteria for dementia associated with Parkinson's disease
Murat Emre et al.
MOVEMENT DISORDERS (2007)
Relation of diabetes to mild cognitive impairment
Jose A. Luchsinger et al.
ARCHIVES OF NEUROLOGY (2007)
Type 2 diabetes and the risk of Parkinson's disease
Gang Hu et al.
DIABETES CARE (2007)
Diabetes is related to cerebral infarction but not to AD pathology in older persons
Z. Arvanitakis et al.
NEUROLOGY (2006)
Reduced risk factors for vascular disorders in Parkinson disease patients - A case-control study
G Scigliano et al.
STROKE (2006)
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy
John R. Harsh et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease:: review and hypothesis
WQ Qiu et al.
NEUROBIOLOGY OF AGING (2006)
Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk
KM Powers et al.
PARKINSONISM & RELATED DISORDERS (2006)
Risk of dementia in diabetes mellitus: a systematic review
GJ Biessels et al.
LANCET NEUROLOGY (2006)
Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study
B Ravina et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping
R Juh et al.
NEUROSCIENCE RESEARCH (2005)
The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem
E Alvarez et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease
L Ho et al.
FASEB JOURNAL (2004)
Insulin and neurodegenerative disease: shared and specific mechanisms
S Craft et al.
LANCET NEUROLOGY (2004)
Mild cognitive impairment as a diagnostic entity
RC Petersen
JOURNAL OF INTERNAL MEDICINE (2004)
Rivastigmine for dementia associated with Parkinson's disease
M Emre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation
T Dehmer et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
I Leroi et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2004)
Prevalence and characteristics of dementia in Parkinson disease - An 8-year prospective study
D Aarsland et al.
ARCHIVES OF NEUROLOGY (2003)
Emerging roles of PPARs in inflammation and immunity
RA Daynes et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease
T Breidert et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
D Aarsland et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review
S Hoyer
JOURNAL OF NEURAL TRANSMISSION (2002)
Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease
D Offen et al.
NEUROSCIENCE LETTERS (2001)
Insulin signalling and the regulation of glucose and lipid metabolism
AR Saltiel et al.
NATURE (2001)
Intracerebroventricular insulin enhances memory in a passive-avoidance task
CR Park et al.
PHYSIOLOGY & BEHAVIOR (2000)
Share Paper
